New Evidence on the Impact of Cervical Cancer Screening and Treatment Using HPV DNA Tests, Visual Inspection or Cytology
Further, a 2007 study that followed over 49,000 women in southern India for seven years reported an overall VIA-associated reduction in cervical cancer incidence and mortality of 25 percent and 35 percent respectively for women ages 30 to 59, with reductions of 38 percent and 66 percent in the 30 to 39 age group (compared with a control group where women received standard care focusing on health education and provision of screening services on request).
Sankaranarayanan has noted the challenges of interpreting the varying results from the two Indian studies and observed that the treatment rate among VIA-positive women was much higher in the southern Indian trial than in the Osmanabad trial, which may be a factor in the different study results.
Should we promote VIA-based programs?
Taking into account the overall body of evidence related to using HPV DNA testing or VIA, the ACCP recommends that, once HPV testing becomes feasible and affordable, programs should consider introducing and scaling up HPV testing as soon as possible as the primary screening method, and utilizing Pap or VIA testing as a triage to evaluate those with HPV-positive test results.
Add A New CommentWe value and respect the experiences of all of our HerWriters, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice although we hope you can gain knowledge from their insight.
Add A New CommentComments
There are no comments yet. Be the first to get the conversation started.